DrugPatentWatch Database Preview
Verapamil hydrochloride - Generic Drug Details
What are the generic drug sources for verapamil hydrochloride and what is the scope of verapamil hydrochloride freedom to operate?
Verapamil hydrochloride
is the generic ingredient in seven branded drugs marketed by Mylan, Recro Gainesville, Gd Searle Llc, Mt Adams, Abraxis Pharm, Bedford, Hospira, Intl Medication, Luitpold, Marsam Pharms Llc, Smith And Nephew, Solopak, Amneal Pharms Co, Exela Pharma Scs Llc, Somerset Theraps Llc, Pfizer, Apotex Corp, Cadila Pharms Ltd, Glenmark Generics, Ivax Sub Teva Pharms, Par Pharm, Pliva, Sun Pharm Inds Inc, Actavis Elizabeth, Heritage Pharms Inc, Mutual Pharm, Sun Pharm Industries, Warner Chilcott, Watson Labs, and Yaopharma Co Ltd, and is included in sixty-four NDAs. Additional information is available in the individual branded drug profile pages.There are seventeen drug master file entries for verapamil hydrochloride. Forty-one suppliers are listed for this compound.
Summary for verapamil hydrochloride
| US Patents: | 0 |
| Tradenames: | 7 |
| Applicants: | 30 |
| NDAs: | 64 |
| Drug Master File Entries: | 17 |
| Suppliers / Packagers: | 41 |
| Bulk Api Vendors: | 80 |
| Clinical Trials: | 107 |
| Patent Applications: | 3,727 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for verapamil hydrochloride |
| DailyMed Link: | verapamil hydrochloride at DailyMed |
Pharmacology for verapamil hydrochloride
| Drug Class | Calcium Channel Blocker |
| Mechanism of Action | Calcium Channel Antagonists Cytochrome P450 3A4 Inhibitors Cytochrome P450 3A Inhibitors P-Glycoprotein Inhibitors |
Medical Subject Heading (MeSH) Categories for verapamil hydrochloride
Synonyms for verapamil hydrochloride
| ( inverted question mark)-Verapamil hydrochloride |
| (??)-Verapamil hydrochloride |
| (?)-Verapamil hydrochloride |
| (+-)-5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile monohydrochloride |
| (+-)-Verapamil hydrochloride |
| (+/-)-VERAPAMIL HYDROCHLORIDE |
| (+/-)-Verapamil hydrochloride, >=99% (titration), powder |
| (+/-)-Verapamil hydrochloride, pharmaceutical secondary standard; traceable to USP and PhEur |
| (+/-)-Verapamil, Hydrochloride |
| (S)-(-)-Verapamil Hydrochloride |
| (y)-Verapamil hydrochloride |
| 152-11-4 |
| 152V114 |
| 2-(3,4-dimethoxyphenyl)-5-[[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino]-2-isopropylpentanenitrile hydrochloride |
| 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-isopropyl-pentanenitrile hydrochloride |
| 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-propan-2-yl-pentanenitrile hydrochloride |
| 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile hydrochloride |
| 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile;hydrochloride |
| 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile hydrochloride |
| 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-isopropylpentanenitrile hydrochloride |
| 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl]methylamino}-2-(methy lethyl)pentanenitrile, chloride |
| 23313-68-0 |
| 36622-29-4 |
| 38176-10-2 |
| 5-((3,4-dimethoxyphenethyl)(methyl)amino)-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile hydrochloride |
| 5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile monohydrochloride |
| 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile Hydrochloride |
| 54236-EP2305219A1 |
| 54236-EP2308562A2 |
| A816666 |
| AB0018370 |
| AC-16228 |
| AC-8483 |
| AC1L1Y4V |
| AC1Q3CE8 |
| Akilen |
| AKOS005267117 |
| AN-7969 |
| Anpec |
| API0024301 |
| Apo-Verap |
| ARONIS24174 |
| Arpamyl LP |
| AS-16018 |
| BBC/320 |
| BC210130 |
| Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-, monohydrochloride |
| Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-, monohydrochloride, (+-)- |
| Benzeneacetonitrile,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-.alpha.-(1-methylethyl)-, monohydrochloride |
| Berkatens |
| BG0353 |
| BIV1326 |
| C27H38N2O4.HCl |
| C27H39ClN2O4 |
| Calan (TN) |
| Calan SR |
| Calaptin |
| Calaptin 240 SR |
| Calcan hydrochloride |
| Cardiabeltin |
| Cardiagutt |
| Cardibeltin |
| Cardioprotect |
| CAS-152-11-4 |
| Caveril |
| CC-35585 |
| CCG-39491 |
| CHEMBL1280 |
| Civicor |
| Civicor Retard |
| Coraver |
| Cordilox SR |
| Corpamil |
| Covera |
| Covera-HS |
| Covera-hs (TN) |
| CS-1685 |
| D-365 hydrochloride |
| D00619 |
| Dignover |
| Dilacoran HTA |
| DOQPXTMNIUCOSY-UHFFFAOYSA-N |
| DSSTox_CID_14095 |
| DSSTox_GSID_34095 |
| DSSTox_RID_79114 |
| DTXSID2034095 |
| Durasoptin |
| EINECS 205-800-5 |
| Elthon |
| EN300-124002 |
| EU-0101237 |
| Falicard |
| Finoptin |
| Flamon |
| FT-0603360 |
| FT-0655647 |
| Geangin |
| Harteze |
| Hexasoptin |
| Hexasoptin Retard |
| HMS1568M04 |
| HMS1922J16 |
| Hormitol |
| HSDB 3928 |
| HY-A0064 |
| I06-0615 |
| Ikacor |
| Ikapress |
| IN1425 |
| Inselon |
| Iproveratril hydrochloride |
| Isoptin Retard |
| Isoptin SR |
| Isoptine |
| Isoptino |
| Isotopin hydrochloride |
| Izoptin |
| Jenapamil |
| K-4825 |
| Lekoptin |
| Lodixal |
| LP01237 |
| LS-161199 |
| LU 20175 |
| Magotiron |
| Manidon |
| Manidon Retard |
| MFCD00055208 |
| MLS000069485 |
| MLS001055442 |
| MLS002222213 |
| MolPort-002-915-466 |
| NCGC00024710-03 |
| NCGC00094479-01 |
| NCGC00094479-02 |
| NCGC00094479-03 |
| NCGC00094479-04 |
| NCGC00094479-05 |
| NCGC00258732-01 |
| NCGC00261922-01 |
| Novapamyl LP |
| Novo-Veramil |
| NSC 135784 |
| NSC 272366 |
| NSC-272366 |
| NSC-657799 |
| NSC-759589 |
| NSC272366 |
| NSC657799 |
| NSC759589 |
| Nu-Verap |
| Opera_ID_1210 |
| OR075078 |
| OR245357 |
| Ormil |
| Pharmakon1600-02300307 |
| Praecicor |
| Prestwick_440 |
| Q-201923 |
| Quasar |
| R(+)-VERAPAMIL |
| R853 |
| Rapam |
| Robatelan |
| s4202 |
| SC-18887 |
| SCHEMBL33296 |
| SMR000059109 |
| SPECTRUM2300307 |
| ST066908 |
| ST24050346 |
| Tox21_201180 |
| Tox21_501237 |
| Univex |
| V 4629 |
| Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl-, monohydrochloride |
| Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl-,monohydrochloride |
| Vasolan (TN) |
| Vasomil |
| Vasopten |
| Vera-Sanorania |
| VERA? HYDROCHLORIDE |
| Verabeta |
| Veracaps SR |
| Veracor |
| Verahexal |
| Veraloc |
| Veramex |
| Veramil |
| Verapamil (hydrochloride) |
| Verapamil Acis |
| Verapamil AL |
| Verapamil Atid |
| Verapamil Basics |
| Verapamil chloridrate |
| Verapamil Ebewe |
| Verapamil HCl |
| Verapamil Henning |
| Verapamil Hydrochloride (Isoptin, Iproveratril, Calan) |
| Verapamil hydrochloride (JP17/USP) |
| Verapamil hydrochloride [USAN:JAN] |
| Verapamil hydrochloride [USAN:USP:JAN] |
| Verapamil Hydrochloride 1.0 mg/ml in Methanol (as free base) |
| Verapamil hydrochloride, European Pharmacopoeia (EP) Reference Standard |
| Verapamil hydrochloride, United States Pharmacopeia (USP) Reference Standard |
| Verapamil Injection |
| Verapamil MSD |
| Verapamil NM |
| Verapamil NM Pharma |
| Verapamil Nordic |
| Verapamil PB |
| Verapamil Riker |
| Verapamil SR |
| Verapamil Verla |
| Verapamil-AbZ |
| VERAPAMILHYDROCHLORIDE |
| Verapamyl hydrochloride |
| Verapin |
| Verapress 240 SR |
| Verasal |
| Verasifar |
| Veratensin |
| Verdilac |
| Verelan (TN) |
| Verelan SR |
| Veroptinstada |
| Verpamil |
| Vetrimil |
| Vortac |
| Z2210978706 |
| ZX-AFC000544 |
| ZX-AS004533 |
US Patents and Regulatory Information for verapamil hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pliva | VERAPAMIL HYDROCHLORIDE | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 072922-001 | Mar 1, 1996 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Mutual Pharm | VERAPAMIL HYDROCHLORIDE | verapamil hydrochloride | TABLET;ORAL | 070482-001 | Sep 24, 1986 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Mt Adams | ISOPTIN | verapamil hydrochloride | TABLET;ORAL | 018593-002 | Mar 8, 1982 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Marsam Pharms Llc | VERAPAMIL HYDROCHLORIDE | verapamil hydrochloride | INJECTABLE;INJECTION | 072233-001 | Feb 26, 1993 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for verapamil hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Gd Searle Llc | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-002 | Feb 26, 1996 | ➤ Sign Up | ➤ Sign Up |
| Gd Searle Llc | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-001 | Feb 26, 1996 | ➤ Sign Up | ➤ Sign Up |
| Gd Searle Llc | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-001 | Feb 26, 1996 | ➤ Sign Up | ➤ Sign Up |
| Recro Gainesville | VERELAN | verapamil hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 019614-001 | May 29, 1990 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Follow DrugPatentWatch: